Fulgent Genetics (FLGT) Projected to Post Earnings on Friday
Fulgent Genetics (FLGT) is projected to release its Q4 2025 earnings before the market opens on Friday, February 27th, with analysts forecasting earnings of $0.02 per share and $85.38 million in revenue. The company currently has a market capitalization of $719.28 million and a negative P/E ratio of -16.74, while Wall Street analysts hold a consensus "Hold" rating with an average $32.00 price target. Insider selling has been observed, and institutional investors collectively own 48.06% of the stock.
Allianz Asset Management GmbH Increases Stake in Fulgent Genetics, Inc. $FLGT
Allianz Asset Management GmbH significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 119.6% in the third quarter of 2025, bringing its total holdings to 90,869 shares valued at approximately $2.05 million. This move is part of broader institutional investor activity, with several other hedge funds also modifying their positions in the company. Analyst sentiment for Fulgent Genetics is mixed, with an average "Hold" rating and a consensus price target of $32.00, while insider selling has also been noted recently.
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. Management will host a conference call on the same day at 8:30 AM ET to discuss the results and answer questions, with a live audio webcast available on the company's investor relations website. Fulgent is a technology-based company with established laboratory services and a therapeutic development business focused on cancer drug candidates.
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics, Inc. announced it will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. Following the release, management will host a conference call at 8:30 AM ET to discuss the results and answer questions. The call will be accessible via live audio webcast on the Investor Relations section of the company's website.
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. The company will also host a conference call for investors on the same day at 8:30 AM ET to discuss the results and answer questions. Fulgent is a technology-based company with established laboratory services and therapeutic development businesses, aiming to transition into a fully integrated precision medicine company.
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. Following the release, management will host a conference call at 8:30 AM ET to discuss the results and answer questions. The call will be accessible via a live audio webcast on the Investor Relations section of the company's website.
FLGT to acquire Bako & StrataDx assets to expand pathology platform
The article states that FLGT (likely Fulgent Genetics or a similar company, though not fully specified in the provided content) is planning to acquire assets from Bako and StrataDx. This acquisition is intended to expand FLGT's pathology platform.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Recommendation of "Moderate Buy" by Analysts
Five analysts have given Fulgent Genetics (NASDAQ:FLGT) an average recommendation of "Moderate Buy," with a consensus 12-month target price of $32.00. The company recently beat earnings estimates but remains unprofitable, with insiders selling shares in the last 90 days. Institutional investors hold a significant portion of the stock.
(FLGT) as a Liquidity Pulse for Institutional Tactics
This article analyzes Fulgent Genetics Inc. (FLGT), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also details how users can access real-time signals and personalized alerts for FLGT.
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) institutional investors lost 6.9% last week but have benefitted from longer-term gains
Institutional investors, who collectively own 57% of Fulgent Genetics (NASDAQ:FLGT), experienced a 6.9% loss last week, despite a 54% one-year return. The company's ownership structure shows that the top five shareholders control about 50% of the business, with CEO Ming Hsieh being the largest individual shareholder at 28%. While institutional ownership provides credibility, the concentration of ownership among a few key players and insiders suggests potential influence on company decisions, and investors are advised to consider other risk factors and analyst forecasts.
Is Fulgent Genetics (NASDAQ:FLGT) A Risky Investment?
Fulgent Genetics (NASDAQ:FLGT) carries some risk due to its current unprofitability, having lost money on an earnings before interest and tax (EBIT) basis and burning through cash. However, the company holds a significant cash balance of US$373.4 million net of debt, which should sustain its growth efforts for at least two years. While the balance sheet appears robust, the lack of consistent free cash flow generation introduces an element of concern.
What Does The Institutional Ownership Tell Us About Fulgent Genetics?
Institutional investors own 57% of Fulgent Genetics (NASDAQ:FLGT), making them the largest shareholder group, though they experienced a 6.9% loss last week. The top 5 shareholders control approximately 50% of the company, and the CEO, Ming Hsieh, is the largest individual shareholder with 28%. Despite the recent dip, the company has seen a 54% one-year return for shareholders, highlighting the significant influence institutional and key individual holdings have on its stock performance.
(FLGT) Risk Channels and Responsive Allocation
This article analyzes Fulgent Genetics Inc. (FLGT), highlighting weak near-term sentiment but strong mid and long-term outlooks. It identifies a 32.0:1 risk-reward setup targeting a 9.3% gain versus 0.3% risk, and provides three AI-generated trading strategies: Long Position, Momentum Breakout, and Risk Hedging, with specific entry, target, and stop-loss levels.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Recommendation of "Moderate Buy" from Analysts
Fulgent Genetics (NASDAQ:FLGT) has received a consensus "Moderate Buy" recommendation from analysts, with an average one-year target price of $32.00. This comes despite the company reporting a negative net margin and negative return on equity, though its recent quarterly results did beat analyst EPS and revenue expectations. Insider selling of shares has occurred, while institutional investors like Acadian Asset Management and JPMorgan Chase & Co. have significantly increased their holdings.
Fulgent Will Acquire Two Laboratories
El Monte-based Fulgent Genetics is set to acquire Bako Diagnostics and StrataDx for nearly $56 million from cash on hand. These acquisitions aim to expand and strengthen Fulgent's diagnostic services, particularly in pathology testing, and leverage its investments in AI. The deals are expected to close in the first half of 2026, pending regulatory approvals.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Pomerantz LLP is investigating potential securities fraud claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of its investors. This investigation follows a disclosure by Fulgent on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice concerning potential false claims related to the Uninsured Program. Following this news, Fulgent's stock price declined by 2.61% over two trading sessions.
(FLGT) Movement as an Input in Quant Signal Sets
This article provides a detailed analysis of Fulgent Genetics Inc. (NASDAQ: FLGT) based on AI-generated signals, highlighting strong near-term sentiment with a long-term positive bias. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key support/resistance levels. The analysis points to an exceptional 33.5:1 risk-reward setup, targeting a 10.0% gain against a 0.3% risk.
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 6.6% Over the Past Week
Institutional investors hold a significant 56% ownership in Fulgent Genetics, Inc. (NASDAQ:FLGT), indicating their considerable influence over the company's stock, which has seen a 6.6% increase in the past week and a 49% return over the last year. The CEO, Ming Hsieh, is the largest shareholder with 28% of outstanding shares, alongside other top shareholders, collectively controlling about 50% of the company. Despite recent insider selling, strong insider holdings suggest alignment with shareholders, while individual investors hold a 10% stake.
Health Check: How Prudently Does Fulgent Genetics (NASDAQ:FLGT) Use Debt?
Fulgent Genetics (NASDAQ:FLGT) has a strong financial position with substantial net cash, reporting US$373.4m net cash as of September 2025. Despite operating at a loss and burning cash, the company's significant cash reserves provide ample runway for growth for at least two years. The analysis highlights that its balance sheet is robust, negating concerns about its debt levels.
Health Check: How Prudently Does Fulgent Genetics (NASDAQ:FLGT) Use Debt?
Fulgent Genetics (NASDAQ:FLGT) has a strong financial position with significantly more cash than debt, boasting US$373.4m net cash as of September 2025. Despite being a loss-making company with negative EBIT and burning cash, its substantial cash reserves provide a buffer for at least two years of growth spending. The analysis concludes that the company does not have a heavy debt load, making its balance sheet sturdy.
Liquidity Mapping Around (FLGT) Price Events
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT) using AI models, highlighting weak near-term sentiment but strong long-term prospects. It outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis. The report also notes an exceptional 32.4:1 risk-reward short setup.
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Fulgent Genetics, Inc. (NASDAQ: FLGT) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Edelson Lechtzin LLP has initiated an investigation into Fulgent Genetics, Inc. (NASDAQ: FLGT) concerning potential violations of federal securities laws. This follows the company's disclosure of a civil investigative demand from the U.S. Department of Justice regarding alleged false claims for COVID-19 testing. Investors who suffered losses are encouraged to contact the firm for more information.
FLGT to acquire Bako & StrataDx assets to expand pathology platform
Fluidigm Corporation (FLGT) plans to acquire assets from Bako Diagnostics and StrataDx to expand its pathology platform. This strategic move aims to enhance its capabilities in the diagnostic market.
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
Fulgent Genetics, Inc. (FLGT) is set to acquire select assets of Bako Diagnostics and StrataDx for $55.5 million, a move aimed at expanding its laboratory services into anatomic pathology and dermatopathology. This strategic acquisition will strengthen FLGT's customer base, add pathology experts, and enhance its diagnostic capabilities through AI technology and digital pathology infrastructure. The company expects these integrations to improve efficiency, expand its testing menu, and solidify its position as a comprehensive diagnostics provider nationwide.
Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5 million
Fulgent Genetics, Inc. announced its definitive agreement to acquire select assets of Bako Diagnostics and to purchase StrataDx for a combined $55.5 million in cash. This acquisition is set to expand Fulgent's laboratory services business by adding anatomic pathology services and proprietary PCR tests, nearly doubling its pathology sales team and geographic footprint. The company's recent strong third-quarter earnings for 2025 further reinforce its growth trajectory, with Raymond James raising its price target to $36.00 and maintaining an Outperform rating.
Latham & Watkins Advises on Fulgent Genetics’ Acquisition of Bako Diagnostics and StrataDX
Latham & Watkins LLP advised Consonance Capital Partners, Bako Diagnostics, and StrataDx in Fulgent Genetics, Inc.'s acquisition of selected assets of Bako Diagnostics and StrataDx for approximately US$55.5 million. The transaction, involving pathology and dermatopathology laboratories, is expected to close in the first half of 2026 pending regulatory approvals. The acquisition aims to expand Fulgent's laboratory services business.
Latham & Watkins Advises on Fulgent Genetics’ Acquisition of Bako Diagnostics and StrataDX
Latham & Watkins LLP advised Consonance Capital Partners, Bako Diagnostics, and StrataDx on Fulgent Genetics' acquisition of selected assets from Bako Diagnostics and StrataDx for approximately US$55.5 million. The deal, expected to close in the first half of 2026 pending regulatory approvals, involves Fulgent Genetics extending its reach in pathology and dermatopathology. A team of Latham & Watkins attorneys provided comprehensive legal advice across various specializations for the transaction.
Fulgent Genetics to buy Bako Diagnostics assets and StrataDx
Fulgent Genetics is set to acquire assets from Bako Diagnostics and StrataDx for approximately $55.5 million, funded by existing cash. This move is expected to expand Fulgent's pathology testing market presence, broaden its client base and sales team, and leverage its AI and digital pathology investments to enhance efficiency and service quality. The acquisitions are anticipated to close in the first half of next year, pending regulatory approvals.
Fulgent Genetics (FLGT) to Acquire Assets from Bako Diagnostics and StrataDx
Fulgent Genetics (FLGT) plans to acquire assets from Bako Diagnostics and StrataDx for approximately $55.5 million, using existing cash reserves. This strategic move, expected to finalize in the first half of 2026, aims to enhance Fulgent's diagnostic capabilities and expand its laboratory network. Despite financial challenges like declining revenue growth and insider selling, the company maintains strong financial health and liquidity, though investors are advised to exercise caution.
Fulgent Genetics to Acquire Bako Diagnostics and StrataDx
Fulgent Genetics (NASDAQ: FLGT) has announced definitive agreements to acquire specific assets of Bako Diagnostics and to acquire StrataDx for a total of approximately $55.5 million. These acquisitions aim to expand Fulgent's laboratory services platform by adding new products, services, and an expanded national client base and sales team. The deal is expected to close in the first half of 2026, strengthening Fulgent's capabilities in pathology testing, leveraging AI, and increasing its geographic footprint.
Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5 million
Fulgent Genetics, Inc. (NASDAQ:FLGT) is set to acquire assets of Bako Diagnostics and purchase StrataDx for a combined $55.5 million in cash. This acquisition will expand Fulgent's laboratory services by adding anatomic pathology and molecular genetic testing, significantly increasing its pathology sales team and geographic footprint. The move aligns with Fulgent's strategy to strengthen diagnostic services and leverage AI and digital pathology investments, following a strong Q3 2025 earnings report.
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Fulgent Genetics (NASDAQ: FLGT) announced its agreement to acquire selected assets of Bako Diagnostics and the acquisition of StrataDx for a total of approximately $55.5 million in cash. This strategic move aims to expand Fulgent's laboratory services platform by adding new anatomic pathology services, proprietary PCR tests, and a national client base. The acquisitions are expected to enhance Fulgent's pathology testing capabilities, commercial reach, and leverage its investments in digital pathology and AI, with the closing anticipated in the first half of 2026.
Understanding the Setup: (FLGT) and Scalable Risk
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a mid-channel oscillation pattern in play. It details various AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis points to positive near-term sentiment that may erode a mid-term weak bias within a long-term strength context.
Fulgent Genetics (NASDAQ:FLGT) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen downgraded Fulgent Genetics (NASDAQ:FLGT) from a "buy" to a "hold" rating, aligning with the stock's consensus "Hold" rating and an average price target of $32.00. Despite beating recent quarterly revenue and EPS estimates, the company remains unprofitable, and analysts forecast a loss for the current fiscal year. Insider selling has also been noted, with key executives reducing their holdings.
The Technical Signals Behind (FLGT) That Institutions Follow
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT) using AI models, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three institutional trading strategies tailored to different risk profiles. Key findings include an exceptional risk-reward short setup and an ongoing test of resistance levels.
Diametric Capital LP Makes New $3.36 Million Investment in Fulgent Genetics, Inc. $FLGT
Diametric Capital LP has made a new $3.36 million investment in Fulgent Genetics, Inc. (NASDAQ:FLGT), acquiring 168,974 shares, making it their 6th largest holding. Despite recent insider selling, Fulgent Genetics positively beat Q3 earnings estimates with $0.14 EPS on $84.07 million revenue and has an average "Hold" rating from analysts with a $32.00 consensus price target. The company faces a negative net margin of 13.62% and negative ROE.
Jian Xie Sells 1,140 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock
Jian Xie, COO of Fulgent Genetics (NASDAQ:FLGT), sold 1,140 shares of the company's stock on December 2nd for approximately $32,296. This recent sale is part of an ongoing trend, with Xie having sold over 13,000 shares in November and December. Following this transaction, Xie retains 336,749 shares valued at around $9.54 million, representing a 0.34% reduction in his position.
Fulgent Genetics (NASDAQ:FLGT) Insider Sells $30,454.75 in Stock
Hanlin Gao, an insider at Fulgent Genetics (NASDAQ:FLGT), sold 1,075 shares of the company's stock for $30,454.75 on December 2nd, reducing their stake by 0.11%. Despite this insider selling, the company recently reported stronger-than-expected Q3 earnings and revenue, beating consensus estimates. Analysts have a mixed outlook on FLGT, with a consensus "Hold" rating and an average price target of $32.00.
Fulgent Genetics Executives Sell Shares for Tax Obligations
Fulgent Genetics Chief Scientific Officer Hanlin Gao and President Xie Jian, both 10% owners, recently sold shares to cover tax obligations. Gao sold 1,075 shares for $30,456, while Jian sold 1,140 shares for $32,298, both at $28.3318 per share on December 2, 2025. These transactions were related to the vesting of restricted stock units, adjusting their direct and indirect shareholdings in the company.
Fulgent Genetics CSO Gao Hanlin sells $27884 in stock
Fulgent Genetics' Chief Scientific Officer Gao Hanlin sold 943 shares totaling $27,884 to cover tax obligations from vested restricted stock units. Despite past losses, the company shows strong financial health with more cash than debt and is expected to return to profitability, trading near its fair value. Recent Q3 2025 earnings surpassed expectations, leading Raymond James to raise its price target for FLGT, citing strong performance and growth in its core diagnostics business.
Fulgent Genetics (NASDAQ:FLGT) COO Jian Xie Sells 1,198 Shares
Fulgent Genetics COO Jian Xie sold 1,198 shares of the company's stock on November 28th at an average price of $29.57. This transaction, valued at $35,424.86, reduced his position by 0.35%, leaving him with 337,889 shares worth approximately $9.99 million. This sale is part of a pattern of insider selling by Xie, who also sold shares earlier in November and September.
Have Insiders Sold Fulgent Genetics Shares Recently?
Fulgent Genetics (NASDAQ:FLGT) recently saw its COO & President, Jian Xie, sell US$291k worth of shares, representing 4.0% of his total holding. While there has been recent selling, a larger insider purchase by CFO Paul Kim for US$1.6m at a lower price in the last twelve months, combined with high insider ownership of 33%, suggests positive long-term alignment. The article notes some warning signs for the company but emphasizes that strong insider ownership is a good indicator.
Have Insiders Sold Fulgent Genetics Shares Recently?
Fulgent Genetics' COO & President recently sold US$291k worth of stock, reducing their total holding by 4.0%. While there have been no insider purchases in the last three months, a significant purchase by the CFO Paul Kim totaling US$1.6m occurred in the last year at a lower price. Insider ownership remains high at 33%, suggesting alignment between management and shareholders despite recent selling activity.
Fulgent Genetics (FLGT) Price Target Increased by 32.90% to 34.34
The average one-year price target for Fulgent Genetics (FLGT) has been increased by 32.90% to $34.34 per share, up from $25.84. This new target represents an 18.01% increase from the latest closing price of $29.10. The article also details institutional ownership changes, including key holders like Millennium Management and Acadian Asset Management.
Institutional investors are Fulgent Genetics, Inc.'s (NASDAQ:FLGT) biggest bettors and were rewarded after last week's US$132m market cap gain
Institutional investors, holding 49% of Fulgent Genetics, Inc. (NASDAQ:FLGT), benefited significantly from the company's US$132m market cap gain last week, contributing to a 36% one-year return. The CEO, Ming Hsieh, is the largest individual shareholder with 29%, while hedge funds own 5.5% of the company. The article highlights that institutional and insider ownership are key factors in assessing the stock's potential performance.
Fulgent Genetics, Inc. SEC 10-Q Report
Fulgent Genetics, Inc. has released its latest Form 10-Q report, demonstrating significant improvements in financial and operational performance. The report highlights revenue growth to $84.1 million and a reduced net loss, driven by precision diagnostics and strategic acquisitions. The company aims to transition into a fully integrated precision medicine company by focusing on therapeutic development.
Earnings call transcript: Fulgent Genetics Q3 2025 Surpasses EPS Expectations
Fulgent Genetics Inc. (FLGT) surpassed Q3 2025 EPS expectations, reporting $0.14 against a forecasted -$0.22, leading to a 7.62% premarket stock increase. Revenue also exceeded estimates at $84.1 million, prompting the company to raise its full-year revenue guidance to $325 million. The strong performance was driven by growth in Precision Diagnostics and Biopharma Services, ongoing advancements in its therapeutic pipeline, and strategic investments in AI and laboratory efficiencies.
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price Is Out Of Tune With Revenues
Fulgent Genetics (NASDAQ:FLGT) has a high price-to-sales (P/S) ratio of 2.7x, which is significantly above the Healthcare industry average of 1.3x in the US. Despite a recent 4.3% revenue increase, the company has seen a 62% decline in revenue over the last three years, contrasting sharply with the industry's projected 6.6% growth. This analysis suggests Fulgent Genetics' high P/S ratio is unjustified given its declining medium-term revenue trends, potentially putting shareholders at risk of an excessive premium.
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. announced that its management team is scheduled to present at the UBS Global Healthcare Conference on November 10th and the Piper Sandler 37th Annual Healthcare Conference on December 2nd. Live webcasts of these investor conference sessions will be available on the Investor Relations section of Fulgent's website. Fulgent is a technology-based company with both laboratory services and therapeutic development businesses, aiming to become an integrated precision medicine company.
FULGENT GENETICS INC (NASDAQ:FLGT) Beats Q3 2025 Earnings Estimates and Raises Guidance
FULGENT GENETICS INC (NASDAQ:FLGT) exceeded third-quarter 2025 earnings estimates, reporting revenue of $84.1 million and non-GAAP EPS of $0.14, significantly beating analyst predictions for a loss. The company also raised its full-year 2025 non-GAAP EPS guidance to $0.30 per share, leading to a positive market reaction in pre-market trading. Management highlighted strong performance in laboratory services and therapeutic development, particularly with FID-007 and FID-022.
